Regor Therapeutics Group
http://www.regor.com/index.html
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Regor Therapeutics Group
Patent Filing By Former Employees Leads Pfizer To File Trade Secret Suit
Pfizer claims two former employees stole trade secrets relating to its diabetes-obesity GLP-1 receptor agonist research program for their startup Regor Therapeutics. Regor’s $1.5bn deal with Lilly further spurred Pfizer’s concerns.
Evotec Adds To Spate Of Metabolic Deals With Lilly Collaboration
The German biotech inks its fifth metabolic disease collaboration as it teams up with US major Lilly to develop kidney disease and diabetes assets.
Deal Watch: Lilly Teams With Regor On Metabolic Disorders
Chinese firm RareStone licenses Rhythm’s Imcivree in greater China and will help enroll label-expansion studies for the drug. Omeros sells ophthalmic surgery drug Omidria and its commercial team to Rayner Surgical Group.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice